title: [Tolerance of adjuvant treatment combining postoperative intraportal chemotherapy and a systemic treatment based on 5-fluorouracil in colorectal carcinoma with a histologically poor prognosis].
abstract: From April 89 to October 90, 41 patients operated for a Dukes B or C colorectal cancer were randomized to receive 6 courses of adjuvant treatment with (A) 5-FU alone (440 mg/m2 IV bolus 5/21 days) or (B) folinic acid (200 mg/m2 IV bolus 5/21 days) preceding 5-FU (370 mg/m2 in short infusion 5/21 days). Ten patients received also one course of immediate post-operative continuous portal infusion (5-FU 500 mg/m2/day x 7 followed by a 2 hours infusion of mitomycin C 10 mg/m2). The portal treatment was well tolerated (1 case of GI tract disturbances, 1 catheter obstruction). The toxicity of adjuvant systemic treatment was evaluated on 232 courses (125 A, 107 B). Hematologic and skin toxicities, alopecia and nausea-vomiting were mild. The limiting toxicities (expressed as percentages of courses) were stomatitis (grades 2-3: 11.4% A; 22.6% B) and diarrhea (grades 3-4: 7.3% A; 14.2% B; one toxic death was to deplore in arm B from a grade 4 diarrhea). The pilot study has demonstrated the feasibility of the adjuvant treatment proposed; a multicentric randomized trial (expected accrual: 800 patients) has therefore been activated on 11.01.90; all patients will also receive levamisole while radio-therapy will be mandatory for rectal cancer.
authors.affiliation: Département d'Oncologie, Centre Hospitalier Saint-Joseph, Espérance-Clinique Sainte-Elisabeth, Liège, Belgique.
authors.forename: L
authors.initials: L
authors.lastname: Longree
authors.forename: C
authors.initials: C
authors.lastname: Focan
authors.forename: B
authors.initials: B
authors.lastname: Dallemagne
authors.forename: M
authors.initials: M
authors.lastname: Delforge
authors.forename: C
authors.initials: C
authors.lastname: Jehaes
authors.forename: R
authors.initials: R
authors.lastname: Malherbe
authors.forename: V
authors.initials: V
authors.lastname: Mazy
authors.forename: S
authors.initials: S
authors.lastname: Markiewicz
authors.forename: J
authors.initials: J
authors.lastname: Weerts
authors.forename: R
authors.initials: R
authors.lastname: Lombard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010865:Pilot Projects; D011169:Portal Vein
chemical_list: D016685:Mitomycin; D002955:Leucovorin; D005472:Fluorouracil
vernacular_title: Tolérance d'un traitement adjuvant associant une chimiothérapie intraportale post-opératoire et un traitement systémique à base de 5-Fluorouracil dans les carcinomes colorectaux de stades histopronostiques défavorables.